Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 14NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 14Prostatic Neoplasms 10Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3HIV Infections 2Acquired Immunodeficiency Syndrome 2Sarcoma, Kaposi 1Recurrence 1Pain 1Myeloid Malignancies 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Lymphoid 1Dendritic Cell Sarcoma, Interdigitating 1Androgen-independent Prostate Cancer 1

Interventions

Rituximab 90Cyclophosphamide 30Lenalidomide 28Bendamustine Hydrochloride 24Prednisone 20Vincristine 19obinutuzumab 17Doxorubicin 16fludarabine 14ibrutinib 13tazemetostat 9idelalisib 9Deoxycholic Acid 9parsaclisib 8Prednisolone 8zanubrutinib 7venetoclax 7tofacitinib 7tisagenlecleucel 5pembrolizumab 5ofatumumab 5ibritumomab tiuxetan 5duvelisib 5Gemcitabine 5Bortezomib 5durvalumab 4aflibercept 4R-CHOP protocol 4Methylprednisolone 4Methotrexate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Follicular × Mitoxantrone × Clear all
NCT00562965 2018-01-09

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Pfizer

Phase 3 Terminated
29 enrolled 14 charts
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡